BioGend Therapeutics Co (ROCO:6733) Shares Outstanding (Basic Average): 123.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6733 BioGend Therapeutics Co Ltd ROCO:6733
73 GF Score
Price NT$25.35
GF Value NT$70.22
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is BioGend Therapeutics Co Shares Outstanding (Basic Average)?

BioGend Therapeutics Co ROCO:6733 -2.50% 73 Shares Outstanding (Basic Average) is 123.5 Mil as of Dec. 2025. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. BioGend Therapeutics Co's average basic shares outstanding for the quarter that ended in Dec. 2025 was 123.5 Mil.


BioGend Therapeutics Co  (ROCO:6733) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


BioGend Therapeutics Co Shares Outstanding (Basic Average) Related Terms


BioGend Therapeutics Co Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for BioGend Therapeutics Co's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGend Therapeutics Co Shares Outstanding (Basic Average) Chart

BioGend Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 101.60 103.40 120.66 123.46 123.46

BioGend Therapeutics Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.46 124.64 122.44 137.85 123.46
ROCO:6733
73GF Score
BioGend Therapeutics Co Ltd ROCO:6733
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGend Therapeutics Co Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 123.5 Mil mean?
BioGend Therapeutics Co (ROCO:6733) has a Shares Outstanding (Basic Average) of 123.5 Mil as of Dec. 2025. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on BioGend Therapeutics Co and its competitors.
Is BioGend Therapeutics Co's Shares Outstanding (Basic Average) too high?
BioGend Therapeutics Co's current Shares Outstanding (Basic Average) is 123.5 Mil. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Shares Outstanding (Basic Average) compare to VRTX and REGN?
BioGend Therapeutics Co's Shares Outstanding (Basic Average) of 123.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on BioGend Therapeutics Co and its competitors. BioGend Therapeutics Co's current Shares Outstanding (Basic Average) is 123.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Shares Outstanding (Basic Average) is 123.5 Mil. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Shares Outstanding (Basic Average) is 123.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?

Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued. The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22. GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6733:

  • Shares Outstanding (Basic Average): 123.5 Mil
  • GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGend Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 115
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score

Get the complete analysis for ROCO:6733

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.35
Price
NT$70.22
GF Value